Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

Company Overview

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Key Stats

• Today's Range: $59.98 to $59.98
• 50-Day Range: $59.50 to $59.98
• 52-Week Range: $27.35 to $60.03
• Volume: N/A
• Average Volume: 1.33 million shs
• Market Capitalization: $2.34 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.43
• Consensus Rating: Hold

LBPH Stock Analysis - Frequently Asked Questions

How were Longboard Pharmaceuticals' earnings last quarter?

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) issued its quarterly earnings results on Thursday, August, 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.10.
Read the conference call transcript.

When did Longboard Pharmaceuticals IPO?

Longboard Pharmaceuticals (LBPH) raised $75 million in an initial public offering on Friday, March 12th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO.

What other stocks do shareholders of Longboard Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Longboard Pharmaceuticals investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/01/2024
• Today: 7/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LBPH
• CIK: 1832168
• Web: www.longboardpharma.com
• Phone: 619-592-9775
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Longboard Pharmaceuticals: $63.43
• High Price Target: $90.00
• Low Price Target: $44.00
• Potential Upside/Downside: +5.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.03%
• Return on Assets: -30.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.97
• Quick Ratio: 15.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 35.92

Miscellaneous

• Outstanding Shares: 39,050,000
• Free Float: 37,234,000
• Market Cap: $2.34 billion
• Optionable: Optionable
• Beta: 1.00